N Engl J Med 1992;326:1250-6.ArticlePubMed 54
Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
Lajud N, Roque A, Cajero M, Gutierrez-Ospina G, Torner L
M., Fisberg, R
Orlistat works by blocking fat absorption in the gut and carries a documented risk of kidney stones and oxalate nephropathy, making it generally unsuitable for people with CKD or a history of kidney stones
In individuals homozygous for the C677T polymorphism in the MTHFR gene, low riboflavin status is associated with elevated plasma homocysteine, and in turn linked with a higher risk of cardiovascular disease and other chronic diseases (13, 14)